Clinical Trials Directory

Trials / Completed

CompletedNCT04367662

Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
99 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation. The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation. On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis. The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.

Conditions

Interventions

TypeNameDescription
PROCEDUREblood samplingblood sampling in hospitalized patient for COVID-19 infection

Timeline

Start date
2020-04-09
Primary completion
2020-05-14
Completion
2020-05-14
First posted
2020-04-29
Last updated
2020-06-09

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04367662. Inclusion in this directory is not an endorsement.